Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEDON: Neoadjuvant Docetaxel +/- Trastuzumab in LABC
NCT00398489Phase 2Unknown
- Sponsor
- Technical University of Munich
- Start
- Oct 2006
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab and docetaxel in breast cancer (2 arms), sponsored by Technical University of Munich. Primary endpoints: Rate of pathologic complete remission (pCR) after neoadjuvant therapy in HER2-positive patients at Week 19, Rate of pathologic complete remission (pCR) after neoadjuvant therapy in HER2-negative patients at Week 19 and 2 more. Status: unknown.
02
Drugs
trastuzumabdocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00398489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00398489.